Efficient infection of mature skeletal muscle with herpes simplex virus vectors by using dextran sulfate as a co-receptor

Gene Therapy

Volumn 6, Issue 9, 1999, Pages 1536-1544

  Yeung, S N ^a   Bockhold, K ^a   Tufaro, F ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dextran sulfate; Gene therapy; Heparan sulfate; HSV; Muscle

Indexed keywords

CHONDROITIN ABC LYASE; DEXTRAN SULFATE; GELATINASE A; HEPARAN SULFATE; VIRUS RECEPTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; GENE TARGETING; HERPES SIMPLEX VIRUS; MOUSE; MUSCLE DEVELOPMENT; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; VIRUS INFECTIVITY;

AGING; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXTRAN SULFATE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MUSCLE, SKELETAL; RECEPTORS, VIRUS; SIMPLEXVIRUS; VIRUS INTEGRATION;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; RODENTIA; SIMPLEXVIRUS;

EID: 0032855208     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300980     Document Type: Article

References (66)

1. Blau HM, Springer ML. Muscle-mediated gene therapy. New Engl J Med 1995; 333: 1554-1556.
2. van Deutekom JC et al. Implications of maturation for viral gene delivery to skeletal muscle. Neuromusc Dis 1998; 8: 135-148.
3. Howell JM et al. High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum Gene Ther 1998; 9: 629-634.
4. Isaka Y et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996; 2: 418-423.
5. Pauly DF et al. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Therapy 1998; 5: 473-480.
6. Bohl D, Heard JM. Modulation of erythropoietin delivery from engineered muscles in mice. Hum Gene Ther 1997; 8: 195-204.
7. Takeda S. (Gene therapy to muscle diseases: perspective and issues on basic research). Nippon Rinsho (Japanese Journal of Clinical Medicine) 1997; 55: 3114-3119.
8. Tsurumi Y et al. Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation 1997; 96 (9 Suppl): II-382-388.
9. Svensson EC, Tripathy SK, Leiden JM. Muscle-based gene therapy: realistic possibilities for the future. Molec Med Today 1996; 2: 166-172.
10. van Deutekom JC, Hoffman EP, Huard J. Muscle maturation: implications for gene therapy. Molec Med Today 1998; 4: 214-220.
11. Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Molec Genet 1993; 2: 1847-1851.
12. Acsadi G et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs (see comments). Nature 1991; 352: 815-818.
13. Karpati G, Acsadi G. The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases. Muscle Nerve 1993; 16: 1141-1153.
14. Smith TA et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
15. Acsadi G et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Molec Genet 1994; 3: 579-584.
16. Yang Y et al. Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Nat Acad Sci USA 1994; 91: 4407-4411.
17. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Nat Acad Sci USA 1995; 92: 1401-1405.
18. Huard J et al. Differential short-term transduction efficiency of adult versus newborn mouse tissues by adenoviral recombinants. Exp Molec Pathol 1995; 62: 131-143.
19. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
20. Huard J et al. LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. Hum Gene Ther 1997; 8: 439-452.
21. Feero WG et al. Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther 1997; 8: 371-380.
22. Huard J et al. Gene transfer to muscle using herpes simplex virus-based vectors. Neuromusc Dis 1997; 7: 299-313.
23. Huard J et al. The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. J Virol 1996; 70: 8117-8123.
24. Huard J, Goins WF, Glorioso JC. Herpes simplex virus type 1 vector mediated gene transfer to muscle. Gene Therapy 1995; 2: 385-392.
25. Inui K, Okada S, Dickson G. Gene therapy in Duchenne muscular dystrophy. Brain Dev 1996; 18: 357-361.
26. Ragot T et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mds mice. Nature 1993; 361: 647-650.
27. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL. Adenovirus as an expression vector in muscle cells in vivo. Proc Nat Acad Sci USA 1992; 89: 2581-2584.
28. Vincent N et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet 1993; 5: 130-134.
29. Spear PG et al. Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv Exp Med Biol 1992; 313: 341-353.
30. Shieh MT et al. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 1992; 116: 1273-1281.
31. Fuller AO, Lee WC. Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration. J Virol 1992; 66: 5002-5012.
32. Gruenheid S, Gatzke L, Meadows H, Tufaro F. Herpes simplex virus infection and propagation in a mouse L cell mutant lacking heparan sulfate proteoglycans. J Virol 1993; 67: 93-100.
33. Herold BC et al. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. J Gen Virol 1994; 75: 1211-1222.
34. Banfield BW et al. Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection. Virology 1995; 208: 531-539.
35. Williams RK, Straus SE. Specificity and affinity of binding of herpes simplex virus type 2 glycoprotein B to glycosaminoglycans. J Virol 1997; 71: 1375-1380.
36. Terry-Allison T et al. HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion. J Virol 1998; 72: 5802-5810.
37. Geraghty RJ et al. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998; 280: 1618-1620.
38. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427-436.
39. Geraghty RJ et al. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein. Science 1998; 280: 1618-1620.
40. Whitbeck JC et al. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol 1997; 71: 6083-6093.
41. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55: 4752-4756.
42. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1995; 1: 938-943.
43. Banfield BW et al. Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry pathway. J Virol 1995; 69: 3290-3298.
44. Dyer AP et al. Dextran sulfate can act as an artificial receptor to mediate a type-specific herpes simplex virus infection via glycoprotein B. J Virol 1997; 71: 191-198.
45. Danko I, Wolff JA. Direct gene transfer into muscle. Vaccine 1994; 12: 1499-1502.
46. Davis HL, Michel ML, Whalen RG. Use of plasmid DNA for direct gene transfer and immunization. Ann NY Acad Sci 1995; 772: 21-29.
47. Larrain J, Alvarez J, Hassell JR, Brandan E. Expression of perlecan, a proteoglycan that binds myogenic inhibitory basic fibroblast growth factor, is down-regulated during skeletal muscle differentiation. Exp Cell Res 1997; 234: 405-412.
48. Aikawa J, Esko JD. Molecular cloning and expression of a third member of the heparan. J Biol Chem 1999; 274: 2690-2695.
49. Qing K et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by. Nature Med 1999; 5: 71-77.
50. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for. J Virol 1998; 72: 1438-1445.
51. Monahan PE et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Therapy 1998; 5: 40-49.
52. Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306-312.
53. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997; 8: 659-669.
54. Rendahl KG et al. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat Biotechnol 1998; 16: 757-761.
55. Acsadi G et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Therapy 1996; 7: 129-140.
56. Guerette B et al. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther 1996; 7: 1455-1463.
57. Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995; 6: 1391-1401.
58. Glorioso JC, DeLuca NA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Ann Rev Microbiol 1995; 49: 675-710.
59. Lim F et al. Generation of high-titer defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells. Biotechniques 1996; 20: 460-469.
60. Evrard A, Vian L, Aubert C, Cano JP. An in vitro nucleoside analog screening method for cancer gene therapy. Cell Biol Toxicol 1996; 12: 345-350.
61. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Nat Acad Sci USA 1996; 93: 3525-3529.
62. Hasegawa Y et al. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using removed victors. Am J Resp Cell Molec Biol 1993; 8: 655-661.
63. Asano S et al. US3 protein kinase of herpes simplex virus type 2 plays a role in protecting corneal epithelial cells from apoptosis in infected mice. J Gen Virol 1999; 80: 51-56.
64. Nishiyama Y, Yamada Y, Kurachi R, Daikoku T. Construction of a US3 lacZ insertion mutant of herpes. Virology 1992; 190: 256-268.
65. Meyer G et al. Bovine herpesvirus type 1 glycoprotein H is essential for penetration and propagation in cell culture. J Gen Virol 1998; 79: 1983-1987.
66. Bame KJ, Esko JD. Undersulfated heparan sulfate in a Chinese hamster ovary cell mutant defective in heparan sulfate N-sulfotransferase. J Biol Chem 1989; 264: 8059-8065.